[
    [
        {
            "time": "2021-11-03",
            "original_text": "格隆汇港股聚焦(11.3)︱中国恒大前10个月销售6325亿元，已超过去年全年",
            "features": {
                "keywords": [
                    "中国恒大",
                    "销售",
                    "6325亿元"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(11.3)︱中国恒大前10个月销售6325亿元，已超过去年全年",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "对话复星陈启宇：打卡进博是自我检阅，医药创新要可负担",
            "features": {
                "keywords": [
                    "复星",
                    "陈启宇",
                    "医药创新"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "对话复星陈启宇：打卡进博是自我检阅，医药创新要可负担",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "大健康产业投资并购动态周报 Vol.24",
            "features": {
                "keywords": [
                    "大健康",
                    "投资并购"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大健康产业投资并购动态周报 Vol.24",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "复星医药(02196)：Grand Pharma向印度的公司注册处递交非正式招股说明书",
            "features": {
                "keywords": [
                    "复星医药",
                    "Grand Pharma",
                    "印度",
                    "招股说明书"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196)：Grand Pharma向印度的公司注册处递交非正式招股说明书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "风格要切换到价值股？这些公司正全力回购自家股票",
            "features": {
                "keywords": [
                    "价值股",
                    "回购"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "风格要切换到价值股？这些公司正全力回购自家股票",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "复星医药(02196.HK)：丙硫氧嘧啶片通过仿制药质量和疗效一致性评价",
            "features": {
                "keywords": [
                    "复星医药",
                    "丙硫氧嘧啶片",
                    "一致性评价"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)：丙硫氧嘧啶片通过仿制药质量和疗效一致性评价",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "【广证恒生医药月报】药监局发布新冠抗体药物临床药学研究指导原则，4个国产疫苗进入临床三期",
            "features": {
                "keywords": [
                    "新冠抗体药物",
                    "疫苗",
                    "临床三期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【广证恒生医药月报】药监局发布新冠抗体药物临床药学研究指导原则，4个国产疫苗进入临床三期",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-11-03",
            "original_text": "市场大事件 | 高瓴、红杉加持也没用，医药明星公司上市首日就破发？连续下跌",
            "features": {
                "keywords": [
                    "高瓴",
                    "红杉",
                    "医药明星公司",
                    "破发"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "市场大事件 | 高瓴、红杉加持也没用，医药明星公司上市首日就破发？连续下跌",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]